Nitric oxide (NO) inhibits myocardial glucose transport and metabolism, although the underlying mechanism(s) and functional consequences of this effect are not clearly understood. We tested the hypothesis that NO inhibits the activation of AMP-activated protein kinase (AMPK) and translocation of cardiac glucose transporters (GLUTs; GLUT-4) and reduces lactate production. Ischemia was induced in open-chest dogs by a 66% flow reduction in the left anterior descending coronary artery (LAD). During ischemia, dogs were untreated (control) or treated by direct LAD infusion of (i) nitroglycerin (NTG) (0.5 g⅐kg ؊1 ⅐min ؊1 ); (ii) 8-Br-cGMP (50 g⅐kg ؊1 ⅐min ؊1 ); or (iii) NO synthase inhibitor L-nitro-argininemethylester (40 g⅐kg ؊1 ⅐min ؊1 ; n ‫؍‬ 9 per group). Cardiac substrate oxidation was measured with isotopic tracers. There were no differences in myocardial blood flow or oxygen delivery among groups; however, at 45 min of ischemia, the activation of AMPK was significantly less in NTG (77 ؎ 12% vs. nonischemic myocardium) and 8-Br-cGMP (104 ؎ 13%), compared with control (167 ؎ 17%). Similarly, GLUT-4 translocation was significantly reduced in NTG (74 ؎ 7%) and 8-Br-cGMP (120 ؎ 11%), compared with control (165 ؎ 17%). Glucose uptake and lactate output were 30% and 60% lower in NTG compared with control. Inhibition of NO synthesis stimulated glucose oxidation (67% increase compared with control) but did not affect AMPK phosphorylation, GLUT-4 translocation and glucose uptake. Contractile function in the ischemic region was significantly improved by NTG and L-nitro-argininemethylester. In conclusion, in ischemic myocardium an NO donor inhibits glucose uptake and lactate production via a reduction in AMPK stimulation of GLUT-4 translocation, revealing a mechanism of metabolic modulation and myocardial protection activated by NO donors.
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heart ͉ ischemia ͉ metabolism N itric oxide (NO) affects myocardial substrate utilization, exerting an inhibitory action on myocardial glucose uptake and metabolism, although the underlying mechanisms and functional implications of this effect, in vivo, remain poorly understood. Exogenous NO, by means of its second messenger cGMP, inhibits glucose uptake and utilization in ischemic (1) as well as nonischemic isolated hearts (2) and in quiescent myocytes (3) . Endogenous NO is likely to be responsible for a tonic inhibition of cardiac carbohydrate metabolism, as indicated by the marked elevation of glucose uptake, under basal conditions, in isolated hearts from endothelial NO synthase (NOS) knockout mice (4) . This effect is not peculiar to in vitro preparations, because NOS blockade enhances cardiac glucose uptake and oxidation and reduces free fatty acid (FFA) utilization in conscious dogs (5, 6) . Notably, NO synthesis increases in ischemic myocardium (7, 8) ; however, the metabolic effects of endogenous NO under this pathological condition remain unclear.
During ischemia, glucose uptake and glycolytic flux are markedly accelerated and assume a critical role in preserving myocyte function (9-11). Ischemia activates glucose transport via translocation of the glucose transporter (GLUT) GLUT-4 from an intracellular pool to the sarcolemma (12, 13) . The mechanisms are still unclear, but a critical role is likely played by activation of AMP-activated protein kinase (AMPK) (14) , a serinethreonine kinase activated via phosphorylation (15) that is emerging as a major stress sensor and regulator of energy turnover (16) . During cardiac ischemia, AMPK stimulates GLUT-4 translocation, glucose uptake, and glycolysis (14, 17) .
Clinically, NO donors such as nitroglycerin (NTG) have been widely used in the treatment of angina for more than a century (18) and are commonly believed to exert a metabolic effect by means of indirect actions (i.e., by lowering ventricular work and͞or by improving coronary perfusion), yet they may also directly alter myocardial glucose metabolism. The effects of NO on AMPK activation, GLUT-4 translocation, glucose uptake and oxidation, and lactate production in ischemic myocardium have not been investigated.
In this study, we tested the hypothesis that NO, by means of cGMP, reduces myocardial glucose uptake and lactate production during low-flow ischemia by inhibiting AMPK activation and GLUT-4 translocation. Regional contractile function and substrate uptake and oxidation were measured in ischemic canine myocardium in vivo. Also, GLUT-4 translocation, AMPK phosphorylation, and the activation state of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) [a key enzyme of the glycolytic pathway known to be inhibited by NO in vitro (19, 20) ] and of pyruvate dehydrogenase (PDH) (the rate-controlling enzyme of carbohydrate oxidation) were measured in cardiac biopsies.
Materials and Methods
The protocol was approved by the Institutional Animal Care and Use Committee (IACUC) of the New York Medical College and conforms to the guiding principles for the care and use of laboratory animals published by the National Institutes of Health.
Surgical Instrumentation. We sedated 36 male mongrel dogs (weight, 23-27 kg) with acepromazine maleate (1 mg͞kg, i.m.), anesthetized with sodium pentobarbital (25 mg͞kg bolus, followed by 3 mg⅐kg⅐h, i.v.) and ventilated with room air. A left lateral thoracotomy was performed, a 5F micromanometer (Millar Instruments, Houston, TX) was positioned in the left ventricle (LV), the left atrium was catheterized for microsphere injection, and a pacing electrode was sutured on the left atrial surface. The proximal left anterior descending coronary artery (LAD) was isolated and artificially perfused in a flow-controlled mode by a peristaltic pump, with arterial blood withdrawn from a carotid artery. The extracorporeal circuit had a side port for pressure measurements and blood sampling. A 22G Teflon cannula was then inserted into an epicardial vein running parallel to the LAD, downstream to the point of cannulation, to withdraw venous blood from the artificially perfused territory. If, during the initial phases of ischemia, we did not observe net lactate production, we assumed that, because of some anatomical variant, the vein was not entirely draining the ischemic LAD territory, and we excluded the dog. However, this problem happened in only three cases. Last, a pair of 5-MHz piezoelectric crystals (Triton Technology, San Diego) was implanted into the LV wall, aligned 1 cm apart and advanced to the midmyocardial layer.
Experimental Protocol. The dogs were divided in four groups of nine dogs each, (i) ischemia (control group), (ii) ischemia plus NTG, (iii) ischemia plus 8-Br-cGMP, and (iv) ischemia plus L-nitro-arginine-methylester (L-NAME) (see Fig. 4 , which is published as supporting information on the PNAS web site, for an outline of protocol).
The initial LAD flow was adjusted to match perfusion pressure and mean arterial pressure. In the control group, 20 min after LAD cannulation, when perfusion flow and hemodynamics were stabilized, we started an i.v. infusion of [9, H]oleate (1.4 Ci͞min; 1 Ci ϭ 37 GBq), [U- 14 C]glucose (20 Ci priming bolus, followed by 0.6 Ci͞min), and L-[1-
13 C]lactate (600 mol priming bolus, followed by 40 mol͞min). At 5 min later, the pacemaker was turned on to maintain heart rate at 160 beats per min. Arterial FFA concentrations were maintained by infusing 0.3 ml͞min of 10% Intralipid throughout the experiment. After 15 min of pacing, the perfusion flow was decreased to 33% of baseline and maintained for 45 min. Paired arterial and venous blood samples were drawn from the perfusion line and from the cardiac vein, respectively, 15 min after starting pacing (baseline) and at 15, 30, and 45 min of ischemia. Regional myocardial blood flow was measured by an injection of 4 ϫ 10 6 stable labeled microspheres (BioPhysics Assay Laboratory, Worcester, MA) through the left atrial catheter at baseline and at 45 min of ischemia while withdrawing arterial blood reference samples from the femoral artery. At the end of the in vivo protocol, 10 ml of lisamine green solution (0.1%, wt͞vol, in normal saline, Fisher Scientific) was injected into the perfusion line to stain and identify the artificially perfused region. Two cardiac punch biopsies were obtained through the artificially perfused region and the nonischemic posterior LV and were immediately freezeclamped in liquid nitrogen. The time from tissue harvesting to clamping was Ϸ3-4 sec. The rest of the perfused region and a piece of the nonischemic posterior LV free wall were excised and rinsed in ice-cold saline, with one portion frozen for later molecular analysis and another portion subdivided in epicardial and endocardial layers and exsiccated for microsphere measurements. The weights of the different samples were added to obtain the total weight of the ischemic region.
In the second group, The NOS competitive inhibitor L-NAME (Sigma-Aldrich) was infused at 40 g⅐kg Ϫ1 ⅐min Ϫ1 . This dose has been shown to inhibit local NO production with no or minimal systemic hemodynamic changes (21) . To rule out possible metabolic effects of L-NAME occurring before the induction of ischemia, pacing was started 30 min, and intracoronary infusion was started at 15 min before ischemia.
In the third group, the NO donor NTG was infused in the LAD at 0.5 g⅐kg Ϫ1 ⅐min Ϫ1 , starting 15 min after the onset of ischemia. As shown in ref. 22 , a similar dose of NTG does not affect systemic hemodynamics. In pilot experiments with normal blood flow in the LAD, this dose caused a 50% increase in blood flow, and we used this change as a reference to determine an equipotent dose of cGMP.
In the fourth group, 8-Br-cGMP (Sigma-Aldrich), which is a cell membrane-permeable analogue of cGMP, was infused in LAD at 50 g⅐kg Ϫ1 ⅐min Ϫ1 . In pilot experiments, this dose mimicked the effect of 0.5 g⅐kg Ϫ1 ⅐min Ϫ1 of NTG on blood flow in LAD; however, the effect of 8-Br-cGMP was not immediate but appeared after 10 min of infusion. Therefore, we started the infusion of 8-Br-cGMP 10, and not 15, min after the onset of low-flow ischemia.
Hemodynamics, Perfusion Flow, and Regional Contractility. LV and aortic pressure, LAD blood flow and pressure, and segmental length between piezoelectric crystals were measured and acquired to calculate dP͞dt max , an index of global LV contractility, and LV segmental fractional shortening, that has been used in similar experimental preparations as an index of regional contractile function (23) . Microsphere content was assessed by neutron activation and absolute transmural, subendocardial, and subepicardial flows were calculated as described (24) .
Total and Labeled Metabolites. The pH; concentrations of oxygen; and total as well as isotope-labeled FFA, lactate, and glucose and 3 H-oleate, 3 H 2 O, and 14 CO 2 were measured in arterial and cardiac venous blood samples as described (6, 25, 26) to calculate myocardial oxygen consumption (MVO 2 ) and the rates of substrate uptake and oxidation in the LAD territory. To measure O 2 delivery to ischemic tissue, arterial oxygen content was multiplied by microsphere-calculated absolute flow at baseline and at 45 min of ischemia. Net lactate uptake is the result of total uptake and output, this latter reflecting nonoxidative glycolysis that normally occurs even in the healthy heart. As in previous studies (27) , we assumed that total lactate uptake measured with the 13 C tracer matched lactate oxidation. Therefore, lactate output could be calculated as the difference between total and net lactate uptake. The 13 C-lactate measurements were limited to selected time points (i.e., baseline and 15 and 45 min of ischemia). MVO 2 and rates of substrate consumption were normalized by weight of the LAD perfused myocardium and expressed, respectively, as ml͞min and mol͞min per g of tissue.
We calculated the hydrogen ion concentration in blood as
ϪpH . Based on arterial and venous concentrations, we then calculated proton production from the artificially perfused territory, an index reflecting changes in intracellular pH. Because of its small value, proton production was expressed as mol͞min per 100 g.
GAPDH and PDH Activities. Enzyme activities of GAPDH and PDH were measured in powdered LV tissue as described (6, 26) . GAPDH activity was assessed in the reverse direction, and total PDH activity was assayed by using a radioenzymatic method. The activity of PDH is expressed as the active form, the total activity (with the addition of Ca 2ϩ , Mg 2ϩ , and dichloroacetate), and the percentage of active PDH (100 ϫ active form͞total activity).
Subcellular Membrane Fractionation and GLUT-4 Translocation.
Plasma membranes were separated from intracellular membranes by floatation-sedimentation in a discontinuous iodoxanol density gradient as established (26) . The GLUT-4 content was assessed in the two membrane fractions by Western blot analysis (26) . GLUT-4 density was then normalized by Na ϩ -K ϩ -ATPase density, and the percentage of increase in GLUT-4 in ischemic vs. nonischemic myocardium, within the same heart, was calculated as an index of translocation͞activation. We did not test GLUT-1 translocation because it previously has been shown to have a minor role compared with GLUT-4 in ischemic myocardium (13) , and the antibody gave inconsistent results against dog protein. We did not test GLUT-1 translocation because the primary antibody gave inconsistent results when tested against dog protein. However, the translocation of GLUT-1 plays a relatively minor role compared with GLUT-4 in ischemic myocardium (13) .
AMPK Phosphorylation. Because AMPK is activated by phosphorylation (15), we used this phosphorylation as an index of the enzymatic activation state. We tested 100 g of total protein extracted from freeze-clamped myocardial tissue by Western blot analysis using a specific monoclonal antibody (1:1000, Cell Signaling Technology, Beverly, MA) directed against phosphorylated Thr-172 groups of the AMPK ␣-subunit. We first tested the specificity of this antibody against canine phospho-AMPK (see Fig. 5 and Supporting Materials and Methods, which are published as supporting information on the PNAS web site, for details). After development, the membranes were stripped and reprobed for total AMPK (1:1,000; Cell Signaling Technology). The phospho-AMPK͞total AMPK ratio was then calculated and used as an index of AMPK activation state, and a comparison was made within the same heart between ischemic and nonischemic myocardium.
Statistical Analysis. Data are presented as mean Ϯ SEM. Statistical analysis was performed by employing STAT (version 2.01; Sigma). Significance was accepted for P Ͻ 0.05. Changes in hemodynamics, regional contractility, and rate of substrate uptake and oxidation over time vs. baseline and differences vs. the control group at matched time points were tested by two-way ANOVA, followed by Tukey's test. Percentage changes in GLUT-4 translocation and AMPK phosphorylation in ischemic vs. nonischemic myocardium within each group was tested by paired t test, and the four groups were compared by one-way ANOVA, followed by Dunnet's test.
Results

Hemodynamics, Myocardial Blood Flow, and Regional LV Contractile
Function. Because changes in myocardial NO levels could alter myocardial flow through recruitment of collateral vessels or shifts in the transmural flow distribution, it is critical to demonstrate that there were no differences among the four groups in subendocardial and subepicardial blood flows. As shown in Table 1 , transmural blood flow and endo͞epicardial flow ratio fell significantly compared with baseline, by Ϸ60% and 45%, respectively, at 45 min of ischemia, and there were no differences among groups in subendocardial or subepicardial flows, or the epicardial͞endocardial (epi͞endo) ratio. Perfusion flow and pressure in the LAD decreased significantly by Ϸ66% and 50%, respectively, in all groups during ischemia ( Table 2 , which is published as supporting information on the PNAS web site); there were no differences among the control, 8-Br-cGMP, and NTG groups; however, LAD pressure was 3-7 mmHg (1 mmHg ϭ 133 Pa) higher in the L-NAME compared with the control group. LV systolic pressure decreased significantly in all groups except the L-NAME group, in which it remained significantly higher (Ϸ10 mmHg) compared with control. Similarly, dP͞dt max fell significantly in all groups with the exception of the L-NAME group, in which the fall was not significant compared with baseline (Table 1) . Fig. 1A displays changes in percentage of shortening of the LV wall in the LAD perfused territory. Positive values indicate active contraction, whereas negative values indicate passive, paradoxical elongation of LV wall during systole and postsystolic shortening. In control and 8-Br-cGMP groups, percentage of shortening was markedly depressed during ischemia. Conversely, in the L-NAME group percentage of shortening did not decrease significantly during ischemia. Percentage of shortening also fell during ischemia in the NTG group; however, it was greater than the control group at 45 min of ischemia. To exclude that these differences could be due to greater oxygen supply to the ischemic myocardium in the L-NAME and NTG groups, we calculated the rate of oxygen delivery by using microsphere-measured transmural blood flow and arterial oxygen content. The rate of oxygen delivery fell significantly during ischemia, with no significant differences among groups (Fig. 6 , which is published as supporting information on the PNAS web site).
MVO2, Cardiac Substrate Uptake, and Substrate Oxidation. MVO 2 fell significantly by Ϸ60% (Fig. 1B) , with no significant differences among groups.
Circulating levels of substrate are an important determinant of myocardial utilization, because cardiac muscle selects preferential metabolites based also on their availability. Therefore, it was important to show that changes in cardiac metabolism that occurred during ischemia and in the presence of pharmacological agents were not due to altered arterial substrate concentrations. We found no significant changes in arterial glucose, lactate, and FFA concentrations during ischemia in any experimental group (Table 3 , which is published as supporting information on the PNAS web site). L-NAME did not cause any significant change in cardiac metabolism after 15 min of infusion in the normoperfused myocardium, before the onset of ischemia (Table 4 , which is published as supporting information on the PNAS web site). As shown in Fig.  1C , FFA uptake decreased significantly during ischemia, with no significant differences among groups. After 15 min of ischemia, glucose uptake increased significantly in all groups, but was Ϸ30% lower in the NTG group compared with control after 30 and 45 min ischemia (Fig. 1D) . Values of net lactate uptake (i.e., the difference between total uptake and output) became negative during ischemia, indicating net lactate production. However, at 30 and 45 min of ischemia, net lactate production was significantly lower in the NTG group compared with control (Fig. 1E) . FFA oxidation fell signif- icantly by 80% (Fig. 1F) , with no significant differences among groups. However, glucose oxidation decreased by Ϸ50% in control, NTG, and 8-Br-cGMP groups but not in the L-NAME group, which remained unchanged from baseline and significantly higher than the control group at 45 min of ischemia (Fig. 1G) . Lactate oxidation decreased significantly during ischemia compared with baseline values only in the NTG group, in which it was also significantly lower than the control group after 45 min of ischemia (Fig. 1H) .
Lactate Release and Hydrogen Ion Production. Lactate release (as measured with the 13 C-tracer method) was significantly increased vs. baseline, by Ϸ180%, in control, L-NAME, and 8-Br-cGMP groups at 45 min but not in the NTG group, which displayed significantly lower values (Ϸ60% reduction) compared with control group (Fig. 2A) . Myocardial proton production partly reflected changes in lactate output. Specifically, it was significantly increased at 15 min of ischemia, and it then returned to baseline values; however, in the NTG group, it was even lower than control at matched time points (Fig. 2B) .
AMPK Phosphorylation and GLUT-4 Translocation.
The percentage of increase in GLUT-4 translocation into the sarcolemma of the ischemic compared with nonischemic myocardium, within the same heart, was significant in all groups (Fig. 3A) . This increase was Ϸ55% lower in NTG group and 27% lower in the 8-Br-cGMP group compared with control. No significant differences were found in the L-NAME group vs. control. Changes in AMPK phosphorylation followed a very similar pattern (Fig. 3B) ; it was significantly increased in ischemic compared with normoperfused myocardium in all groups. However, the increase was more pronounced in the control group (Ͼ160%) than in the NTG (Ͻ90%) and 8-Br-cGMP (Ͻ120%) groups. Also, in this case, no significant differences were found in the L-NAME group vs. control. Representative bands from Western blot analyses (Fig. 3 C and D) show how GLUT-4 concentration in sarcolemma and AMPK phosphorylation were increased during ischemia but to a lesser extent in NTG and 8-Br-cGMP groups compared with control.
GAPDH and PDH Activities. GAPDH activity and the active fraction of PDH did not change significantly in any groups and under any experimental condition (Table 5 , which is published as supporting information on the PNAS web site).
Discussion
The main finding of the present in vivo study is that, in ischemic myocardium, NO supplied by NTG inhibits glucose uptake and lactate production by a reduction in AMPK stimulation of GLUT-4 translocation, revealing a mechanism of metabolic modulation by NO donors. We found that, at 45 min of ischemia, (i) additional NO supplied by an exogenous donor markedly limits ischemia-induced AMPK phosphorylation, GLUT-4 translocation, glucose uptake, and lactate production; (ii) the metabolic effects of 8-Br-cGMP on inhibition of AMPK phosphorylation and GLUT-4 translocation largely mimic those of exogenous NO, strongly suggesting that these latter are mediated by cGMP; and (iii) the inhibition of NO synthesis stimulates glucose oxidation by means of a PDHindependent mechanism and markedly improves contractile function but does not affect AMPK phosphorylation, GLUT-4 translocation, or glucose uptake. None of the administered agents affected systemic hemodynamics, myocardial blood flow, or oxygen delivery to the ischemic territory. Together, these results demonstrate a direct role for NO in the metabolic response to ischemia and suggest that NO donors, a mainstay of antiangina therapy (18) , reduce activation of AMPK and stimulation of glucose uptake and lactate production during myocardial ischemia, and endogenous NO selectively inhibits glucose oxidation.
In this study, we prevented the classic changes in hemodynamics and myocardial blood flow that occur with systemic administration of NOS inhibitors or NO donors; thus, we can conclude that the metabolic and functional changes that we observed were due to direct effects of NO. Previous work (14, 16, 17) and these results suggest that the reduced activation of AMPK, GLUT-4 translocation, glycolysis, and lactate production in dogs receiving the NO donor reflect a cause-effect relationship. AMPK is activated by both a rise in intracellular AMP and a direct phosphorylation by AMPK kinase (15) . This activation occurs typically during ischemia, when phosphorylated AMPK stimulates glucose transport (14) and accelerates glycolysis by activation of phosphofructokinase (17) . Our experiments consistently demonstrate that the reduced AMPK phosphorylation, due to NO, corresponds to less GLUT-4 translocation, reduced glycolysis, and less lactate production. As in our previous study in conscious dogs (6), the activity of GAPDH was not affected by NO; thus, we could not confirm the inhibition by NO on GAPDH previously observed in other cell types in vitro (19, 20) . Therefore, these results suggest that the changes in glycolytic flux due to alterations in NO levels were causally related to AMPK activation state. Because NTG infusion was started after 15 min of ischemia, when glucose uptake was already increased significantly, we speculate that, over the next 30 min, sarcolemmal GLUT-4 were gradually internalized while the translocation of additional transporters was inhibited. However, NTG did not further potentiate the inhibition of glucose oxidation exerted by endogenous NO, probably because the glucose oxidation pathway was already severely depressed.
The metabolic changes observed after inhibition of endogenous NO synthesis are consistent with our previous findings in conscious dogs, in which systemic NOS blockade caused a marked increase in cardiac glucose oxidation but only a transient and much less pronounced increase in glucose uptake (6) . A possible interpretation is that, even if cardiac ischemia increases NO production (7, 8) , the tissue concentration of NO is insufficient to inhibit glucose transport and glycolysis but high enough to suppress glucose oxidation. As reported in ref. 28 , NOS blockade did not increase glucose uptake in ischemic myocardium; however, by using 14 Clabeled glucose, we could unmask an interesting and unexpected discrepancy between rates of uptake and despite increasing glucose oxidation. There was no difference in PDH activation compared with control; therefore, the mechanism of glucose oxidation inhibition by NO remains undetermined. We hypothesize that, in dogs receiving L-NAME, regional fractional shortening was partially preserved as a direct consequence of the restored glucose oxidation. Alternatively, because high concentrations of NO exert a negative inotropic effect (29) and limit mitochondrial respiration (30) , the enhanced glucose oxidation during NOS blockade could be the result, rather than the cause, of the improved contractility and oxygen utilization.
Because we found endogenous NO to be detrimental for metabolism and contractility of the ischemic region, we expected no changes or further impairment of fractional shortening during NTG infusion. Instead, there was a paradoxical improvement of the regional function; fractional shortening was still negative, reflecting systolic bulging, but less than in control hearts, indicating a partial preservation of the LV wall tone and, therefore, a better response to transmural mechanical solicitations during systole. Evidently, the suppression of glucose uptake and lactate production induced by augmented availability of NO had positive consequences for the ischemic heart, most likely because of improved intracellular pH and less impairment in cardiomyocyte function (31) .
These findings indicate that NO donors such as NTG, largely used in the treatment of cardiac ischemia, have direct metabolic effects on myocardium that were previously unsuspected. They exert a ''metabolic protection'' that would add to other critical functions already attributed to endogenous NO in the context of ischemic preconditioning, characterized by increased NO synthesis (32) .
There are several limitations of the present study. First, the blood concentration of NTG achieved in the ischemic territory, equal to Ϸ1 g͞ml, was higher than that found in patients treated with sublingual, transdermal, and i.v. NTG administration (33, 34) . It remains to be determined whether similar effects occur at lower doses. Second, we did not determine the potential metabolic effects of catecholamines and ␤-adrenergic antagonists. Ischemia triggers myocardial and systemic catecholamine release, and many patients with ischemic heart disease are treated with ␤-adrenergic antagonists; thus, the interrelationship among NO, catecholamines, and ␤-adrenergic antagonists merits investigation. Similarly, further experiments will be necessary to explore the effects of NO͞cGMP on postischemia reperfusion. Last, we cannot exclude the possibility that different timing, doses, or NO donors and NOS inhibitors would affect the entity and timing of the observed changes.
In conclusion, we demonstrate that administration of exogenous NO prevents the activation of AMPK in response to ischemia, the subsequent translocation of GLUT-4 into the sarcolemmal membrane, and the ischemia-induced increase in glucose uptake and lactate production. Also, the inhibition of NO synthesis stimulates glucose oxidation by means of a PDH-independent mechanism and markedly improves contractile function but does not affect AMPK phosphorylation, GLUT-4 translocation, and glucose uptake. These mechanisms suggest that the therapeutic actions of NO donors in myocardial ischemia may be partially due to the metabolic effects of these agents.
